SCHEMBL23927439

SCHEMBL23927439

CCOC(=O)c1nnc(Cc2ccc(F)c(Cl)c2F)[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.37
LMNA P02545 3/20 0.37
NPC1 O15118 3/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 2/20 0.37
ALOX15 P16050 2/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
KMT2A Q03164 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KCNH2 Q12809 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ALPL P05186 1/20 0.35
TARBP2 Q15633 1/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30091516 1.00 P2RX7 (0.37) P2RX7LMNANPC1MAPTRAB9A
SCHEMBL23927507 0.90 HPGD (0.40) P2RX7LMNANPC1RAB9ATP53
SCHEMBL30091646 0.84 ALOX15 (0.45) LMNANPC1MAPTRAB9ATP53
SCHEMBL23927454 0.84 ALOX15 (0.45) LMNANPC1MAPTRAB9ATP53
SCHEMBL23927449 0.83 ALOX5 (0.40) P2RX7LMNAMAPTTP53ALOX15
SCHEMBL30091692 0.83 ALOX5 (0.40) P2RX7LMNAMAPTTP53ALOX15
SCHEMBL15964605 0.82 NPC1 (0.43) LMNANPC1RAB9AKMT2AHPGD
SCHEMBL23927464 0.80 TSHR (0.46) NPC1RAB9AALOX15KMT2ANPSR1
SCHEMBL23927468 0.80 TSHR (0.43) P2RX7MAPTRAB9AKMT2ANPSR1
SCHEMBL23927476 0.80 LMNA (0.39) LMNANPC1MAPTRAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 P2RX7 2134/4885LMNA 2659/4885NPC1 2376/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 P2RX7 2134/4885LMNA 2659/4885NPC1 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.